RxDoctor Payments DataLook up a doctor →

Mary Mulcahy, MD

Medical Oncology · Chicago, ILNPI 1306870837

Payments from drug & device makers

$873,327in general payments, 2019–2025

Across 65 payments — averaging $13,436 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma Global Development$244K
  • Boston Scientific$239K
  • Seagen Inc.$185K
  • Genentech, Inc.$78K
  • Biocompatibles UK Ltd$40K
  • Amgen$40K
  • plus $48K from 9 others

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$873,327 in reported general payments places this provider in the 85th percentile of 144 medical oncology providers in Illinois.

See all medical oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$5,032,680
Medicare patients
537
Services billed
187,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →